NEW YORK (GenomeWeb News) — Exosome Diagnostics said today that it has closed a Series B financing round raising $27 million.

New York-based Exosome will use the proceeds of the financing to advance development of its proprietary platform technology for preparing nucleic acids from microvesicles, as well commercial programs for non-invasive, fluid-based molecular diagnostics in oncology, neurodegenerative disease, and other clinical areas.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.